NEW YORK--(BUSINESS WIRE)--Tyme Technologies, Inc. (Tyme, Inc.) (OTC QB:TYMI), a cancer research company focused on developing and commercializing products in the oncology space, announced the appointment of Mario Eisenberger, MD to its Medical Advisory Board. Dr. Eisenberger is renowned with more than 30 years of oncology experience and, as a member the Tyme, Inc. Medical Advisory Board, will offer oversight in clinical and medical affairs. Dr. Eisenberger, in addition to being an accomplished doctor, is a scientist, educator and highly-prized guest speaker. He is currently Professor of urology and oncology at Johns Hopkins University School of Medicine, with a practice specializing in the treatment of cancers of the bladder, kidney, prostate and testicles.
"We are delighted to welcome Dr. Eisenberger to our Medical Advisory Board and look forward to benefitting from his background and expertise"
"We are delighted to welcome Dr. Eisenberger to our Medical Advisory Board and look forward to benefitting from his background and expertise," said Steve Hoffman, President and Chief Executive Officer of Tyme, Inc. "His scientific acumen, as well as his clinical and drug development experience make him an important asset to our research team. Dr. Eisenberger joins our Medical Advisory Board at an exciting juncture for SM-88 and we will look to him for guidance as we pursue future development programs in oncology. His broad global and domestic drug development experience will be beneficial in our efforts to expand our pipeline through internal development and potential strategic alliances."
Dr. Eisenberger joined the faculty of Johns Hopkins as an Associate Professor of oncology and urology in 1993 and became a Professor of both specialties in 1998. Prior to joining Johns Hopkins, he held faculty appointments in oncology and urology at the University of Miami and the University of Maryland. Dr. Eisenberger also served as senior investigator for the Cancer Therapy Evaluation Program of the National Cancer Institute and Chief of Oncology at the Baltimore Veteran's Administration Hospital. He began his career in private practice as a medical oncologist and hematologist.
Dr. Eisenberger completed his MD at the Federal University of Rio de Janeiro. Following an internship in oncology/hematology and residency in medicine at the Michael Reese Hospital and Medical Center in Chicago, he completed a fellowship in medical oncology at the University of Miami School of Medicine.
Dr. Eisenberger has been listed in Best Doctors in America and in Who's Who in the World, has published extensively and has presented on international and national panels. He is a member of the American Association for Cancer Research, the National Prostate Cancer Education Council and the American Society of Clinical Oncology, and he sits on the International Task Force of the American Society of Clinical Oncology. He is certified in medical oncology and internal medicine by the American Board of Internal Medicine.
About Tyme, Inc.
Tyme, Inc. is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme, Inc. is the originator of what it believes to be a novel, proprietary treatment regimen consisting of a rationally-designed combination of therapeutic agents aimed at exploiting the aberrant metabolic characteristics of cancer cells as well as activating the endogenous immune response against tumors. Tyme, Inc.'s approach is hypothesized to permit selective elimination of cancer cells, while simultaneously improving patients' well-being, particularly with respect to pain severity and functional independence.
Tyme, Inc. is currently developing for use in humans SM-88, a proprietary compound, which the company believes to be a first-in-class drug that harnesses the body's own immune defenses to fight tumor cells. SM-88 is a novel combination drug that synergistically targets the unique metabolic features of cancer cells, thus providing a selective method of altering the susceptibility of cancer cells to oxidative stress. Tyme, Inc. has completed a proof-of-concept clinical study for SM-88 in late-stage cancer patients with relapsed or highly refractory disease and is working towards submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), with the goal of beginning a randomized clinical trial in multiple U.S. centers in the near future. Tyme, Inc. anticipates an IND submission to the FDA in the second half of 2015.
For more information, visit our website: www.tymetechnologiesinc.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the factors described in the section captioned "Risk Factors" of Tyme, Inc.'s Current Report on Form 8-K/A filed with the U.S. Securities and Exchange Commission on April 16, 2015 (available at www.sec.gov).
Readers can identify forward-looking statements by terms such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "would" and similar expressions intended to identify forward-looking statements, and forward-looking statements within this press release include statements regarding our drug development strategies, clinical trials and plans for submitting an IND with the FDA. Forward-looking statements reflect the Company's current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, readers should not place undue reliance on these forward-looking statements.